Premium
The Challenge of Antimicrobial Resistance: New Regulatory Tools to Support Product Development
Author(s) -
Tomayko J F,
Rex J H,
Tenero D M,
Goldberger M,
Eisenstein B I
Publication year - 2014
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2014.107
Subject(s) - antibiotics , clinical pharmacology , antibiotic resistance , antimicrobial , pipeline (software) , intensive care medicine , medicine , microbiology and biotechnology , risk analysis (engineering) , engineering ethics , pharmacology , biology , computer science , engineering , programming language
The antibiotic pipeline is thin and lacks diversity, particularly for agents targeting Gram‐negative pathogens. The reasons for our anemic global development pipeline are often summarized as (i) discovery of new antibiotics is difficult, (ii) clinical development of new antibiotics is difficult, and (iii) the economics for new antibiotics are unfavorable for the developer. Here, we review recent efforts directed at the second of these challenges. Clinical Pharmacology & Therapeutics (2014); 96 2, 166–168. doi: 10.1038/clpt.2014.107